Search research articles
Contact Us
Filters
Showing results (11-20 of 20) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 20 results.
Journal of Medicinal Chemistry
|
December 19, 2017
Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase
Sarah E Huff, Faiz Ahmad Mohammed, Mu Yang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry
|
February 9, 2019
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
Tessianna A Misko, Yi-Ting Liu, Michael E Harris, et al.
Stem Cells Translational Medicine
|
April 16, 2018
MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation
Rutulkumar Patel, Yulan Qing, Lucy Kennedy, et al.
American Journal of Cancer Research
|
October 12, 2020
A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer
Davendra Sohal, Smitha Krishnamurthi, Rita Tohme, et al.
Oncotarget
|
August 29, 2015
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
Andrew R Lavik, Fei Zhong, Ming-Jin Chang, et al.
Oncotarget
|
November 8, 2017
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies
Paolo F Caimi, Brenda W Cooper, Basem M William, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 19, 2017
Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule
Md Faiz Ahmad, Intekhab Alam, Sarah E Huff, et al.
Journal of Medicinal Chemistry
|
October 22, 2015
Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators
Md Faiz Ahmad, Sarah E Huff, John Pink, et al.
Progress in Biophysics and Molecular Biology
|
March 6, 2021
An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation
My T Nguyen, Davide Moiani, Zamal Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2019
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
Anjali S Advani, Brenda Cooper, Valeria Visconte, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 20) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 20 results.
Journal of Medicinal Chemistry
|
December 19, 2017
Structure-Guided Synthesis and Mechanistic Studies Reveal Sweetspots on Naphthyl Salicyl Hydrazone Scaffold as Non-Nucleosidic Competitive, Reversible Inhibitors of Human Ribonucleotide Reductase
Sarah E Huff, Faiz Ahmad Mohammed, Mu Yang, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry
|
February 9, 2019
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
Tessianna A Misko, Yi-Ting Liu, Michael E Harris, et al.
Stem Cells Translational Medicine
|
April 16, 2018
MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation
Rutulkumar Patel, Yulan Qing, Lucy Kennedy, et al.
American Journal of Cancer Research
|
October 12, 2020
A pilot clinical trial of the cytidine deaminase inhibitor tetrahydrouridine combined with decitabine to target DNMT1 in advanced, chemorefractory pancreatic cancer
Davendra Sohal, Smitha Krishnamurthi, Rita Tohme, et al.
Oncotarget
|
August 29, 2015
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2
Andrew R Lavik, Fei Zhong, Ming-Jin Chang, et al.
Oncotarget
|
November 8, 2017
Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies
Paolo F Caimi, Brenda W Cooper, Basem M William, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
July 19, 2017
Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule
Md Faiz Ahmad, Intekhab Alam, Sarah E Huff, et al.
Journal of Medicinal Chemistry
|
October 22, 2015
Identification of Non-nucleoside Human Ribonucleotide Reductase Modulators
Md Faiz Ahmad, Sarah E Huff, John Pink, et al.
Progress in Biophysics and Molecular Biology
|
March 6, 2021
An effective human uracil-DNA glycosylase inhibitor targets the open pre-catalytic active site conformation
My T Nguyen, Davide Moiani, Zamal Ahmed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 18, 2019
A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia
Anjali S Advani, Brenda Cooper, Valeria Visconte, et al.
Page
of 2